Drug intelligence / Profile preview

HGP2102-1

Development stage: Phase 3
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HGP2102-1 is an investigational small molecule drug developed by Hanmi Pharmaceutical for the treatment of essential hypertension. It is currently being evaluated in a multicenter, randomized, double-blind Phase 3 clinical trial to assess its efficacy and safety in patients with high blood pressure. The specific mechanism of action for HGP2102-1 has not been disclosed publicly and remains unknown. The drug is administered orally once daily as part of the study protocol[1][2][3][4][6].

Other names: hcp2102hcp-2102hcp 2102hcp2102-1hcp-2102-1hcp 2102-1

Targets

AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on HGP2102-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGP2102-1.

Explore the full profile